Advances and challenges: dendritic cell vaccination strategies for glioblastoma

Advances and challenges: dendritic cell vaccination strategies for glioblastoma

Introduction: Glioblastoma is the most common primary brain tumor in adults and prognosis remains poor with a median survival of approximately 15–17 months. This review provides an overview of recent advances in the field of glioblastoma immunotherapy. Areas covered: Recent advances in dendritic cel...

Full description

Bibliographic Details
Main Authors: Teilo H. Schaller, John H. Sampson
Format: Article
Language:English
Published: Taylor & Francis Group 2017-01-01
Series:Expert Review of Vaccines
Subjects:
glioblastoma
cancer vaccine
dendritic cell
immunotherapy
clinical trials
immunosuppression
t-cell dysfunction
fastdcs
in-vivo dc vaccine
recall antigens
Online Access:http://dx.doi.org/10.1080/14760584.2016.1218762

Internet

http://dx.doi.org/10.1080/14760584.2016.1218762

Similar Items